Literature DB >> 33010653

Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.

Maria Cellerino1, Simona Bonavita2, Margherita Ferrero3, Matilde Inglese4, Giacomo Boffa1.   

Abstract

Entities:  

Keywords:  Breakthrough disease activity; Cladribine; Fingolimod withdrawal; Multiple sclerosis

Mesh：

Substances：

Year:  2020        PMID： 33010653     DOI： 10.1016/j.jns.2020.117156

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  3 in total

1.  Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.

Authors:  Melanie Korsen; Steffen Pfeuffer; Leoni Rolfes; Sven G Meuth; Hans-Peter Hartung
Journal:  J Neurol       Date:  2022-01-09       Impact factor: 6.682

2.  Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.

Authors:  D Ferraro; P Iaffaldano; T Guerra; M Inglese; M Capobianco; V Brescia Morra; M Zaffaroni; M Mirabella; G Lus; F Patti; P Cavalla; M Cellerino; S Malucchi; E Pisano; F Vitetta; D Paolicelli; P Sola; M Trojano
Journal:  J Neurol       Date:  2021-07-22       Impact factor: 4.849

3.  Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report.

Authors:  Riccardo Garbo; Daniela Cutuli; Simone Lorenzut; Gian Luigi Gigli; Daniele Bagatto; Mariarosaria Valente
Journal:  Front Neurol       Date:  2021-12-08       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.